Overview

Nimotuzumab Combined With VMAT in Elderly Patients With Nasopharyngeal Carcinoma

Status:
Recruiting
Trial end date:
2022-05-01
Target enrollment:
0
Participant gender:
All
Summary
To evaluate the efficacy and toxicity of Nimotuzumab combined with VMAT in the treatment of elderly patients with nasopharyngeal carcinoma (> 70 years old), and to provide high-level clinical evidence for the optimal treatment of elderly patients with nasopharyngeal carcinoma.
Phase:
Phase 2
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
Chinese Academy of Medical Sciences
Treatments:
Nimotuzumab
Criteria
Inclusion Criteria:

- Pathology confirmed squamous cell carcinoma of nasopharynx; Aged ≥ 70 years old; Stage
III-IVB diseases according to 8th AJCC Staging; Treatment for the first time; ECOG
scores ≤ 1; Normal hepatic, renal and bone-marrow function; ACE-27 scores ≤2; Life
expectancy≥12 weeks; Can understand and sign the consent.

Exclusion Criteria:

- Past malignancies history (except for non-melanoma skin cancer or cervical carcinoma
in situ or cured prostate cancer of early stage); Allergic to Nimotuzumab; Severe
comorbidities including cardiovascular, cerebral vascular, mental and uncontrolled
diabetes disease; Chemotherapy, surgery or other molecule-target treatment; Severe
malnutrition.